The Form 4 filing was filed on November 18, 2026, the same day as the purchase. This SEC report records changes in an insider's stock ownership.
CG Oncology is a biotechnology company in the healthcare sector. Arthur Kuan serves as its chief executive officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-18 |
| Date of Latest Transaction | 2026-11-18 |
| Buy/Sell | buy |
| Transaction Count | 1 |
| Shares Transacted | 30,000.32 |
| Price | $78.88 |
| Total Transaction Value | $2,366,425.24 |
| Insider | |
| Ticker Symbol | CGON |
| Company | CG Oncology, Inc. |
| Insider Name | Kuan Arthur |
| Insider Title | Chief Executive Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 228,916.32 |
| Position Size Change | 13.11% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a purchase of 30,000.32 CGON shares. It was reported as one transaction with code P, which identifies a share purchase.
What was the average price of the transaction?
The average price was $78.88 per share. That price applies to the single purchase reported for November 18, 2026.
How did this transaction affect the insider's holdings?
Arthur Kuan acquired 30,000.32 shares and reported owning 228,916.32 shares afterward. The shares bought made up 13.11% of his reported shares owned after the purchase.
What's the total transaction value?
The total value was $2,366,425.2416, shown as $2,366,425.24 when rounded to cents. This amount covers the single reported purchase.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Filing footnote text was not available, so any further plan details or other circumstances remain unknown.
For research purposes only; not investment advice.